Drug Profile
M 40
Latest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Unknown
- Developer Nonindustrial source
- Class Antidementias; Neuroprotectants
- Mechanism of Action Neurotransmitter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Jul 2001 No-Development-Reported for Alzheimer's disease in USA (Unknown route)
- 01 Apr 1998 New profile
- 01 Apr 1998 Preclinical development for Alzheimer's disease in USA (Unknown route)